Deere & Company vs Johnson & Johnson — how do they compare? Deere & Company trades at $652.58 (market cap $175.95B), while Johnson & Johnson trades at $255.8 (market cap $618.09B). The key difference: Johnson & Johnson is far larger — about 3.5× Deere & Company's market cap, and Johnson & Johnson pays the higher dividend (2.09%). Which is the better fit depends on your goals — on Pluang, investors hold Deere & Company for 75 Days and Johnson & Johnson for 129 Days on average.
| DE | JNJ | |
|---|---|---|
Market Cap | $175.95B | $618.09B |
Volume | 1,387,231 | 6,050,983 |
Sector | Industrials | Health |
52-Week High | $709.48 | $278.43 |
52-Week Low | $439.11 | $186.00 |
Typical Hold Time | 75 Days | 129 Days |
Enterprise Value | $229.85B | $646.37B |
Dividend Yield | 0.99% | 2.09% |
Signals from Pluang's Aura AI — not financial advice
Deere & Company (DE) trades at $656.87, down 3.8% on the day, reflecting near-term pressure amid a broader bearish technical signal. The stock has demonstrated strong earnings momentum, beating estimates in the last three quarters, but faces headwinds from declining revenue and net income margins. Recent news highlights the company's focus on AI-driven agricultural solutions to counter cyclical downturns, while analyst consensus remains divided with a price target of $731.20 suggesting potential upside from current levels.
The outlook for DE is mixed; solid profitability metrics and consistent cash flow generation support the investment case, but cyclical exposure to agriculture equipment demand and elevated valuation ratios pose risks. Earnings growth and successful execution of technology initiatives are key catalysts for outperformance, though macroeconomic volatility could dampen near-term returns.
Johnson & Johnson (JNJ) trades at $258.45, up 1.44% today, with a bearish technical signal but strong fundamentals including a 21.48% net income margin and consistent earnings beats. The stock is supported by a diversified healthcare portfolio and a recent dividend declaration of $1.34 payable in September 2026. Revenue growth is projected to reach $97.9B in 2026, though net income is expected to moderate. Analyst consensus is bullish with a $286.53 price target, but technical indicators show resistance near $260.
JNJ presents a solid long-term investment opportunity due to its robust profitability, high ROE of 25.74%, and defensive sector positioning. Risks include increasing debt-to-asset ratio (24.06% in 2025) and competitive pressures in pharmaceuticals. The stock's current valuation at a P/E of 29.98 may limit near-term upside, but analyst optimism and dividend reliability support a positive outlook for patient investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Deere is the world's leading manufacturer of agricultural equipment, producing some of the most recognizable machines in the heavy machinery industry. The company is divided into four reportable segments: production and precision agriculture, small agriculture and turf, construction and forestry, and John Deere Capital. Its products are available through an extensive dealer network, which includes over 1,900 dealer locations in North America and approximately 3,700 locations globally. John Deere Capital provides retail financing for machinery to its customers, in addition to wholesale financing for dealers, which increases the likelihood of Deere product sales.
Read more on DE →Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →